Boston Scientific Corporation (BSX) Presents at Citi Annual Global Healthcare Conference 2025 Prepared Remarks Transcript
Boston Scientific Corporation (BSX) Presents at Citi Annual Global Healthcare Conference 2025 Prepared Remarks Transcript
M&A Strategy Strengthens Boston Scientific's Growth Prospects
BSX accelerates growth as a wave of acquisitions boosts core portfolios and fuels expansion into high-growth adjacent markets.
Why Boston Scientific (BSX) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Boston Scientific's Margins Strengthen in Q3: What's Driving It?
BSX posts stronger Q3 margins as growth in EP and WATCHMAN lifts product mix despite tariff pressure.
BSX vs. EW: Which Heart Device Stock Is the Smarter Investment Now?
Boston Scientific's EP breadth, WATCHMAN momentum and acquisitions give it an edge over Edwards in cardiovascular devices.
Boston Scientific (BSX) Upgraded to Buy: Here's What You Should Know
Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BSX's Neuromodulation Prospect Looks Strong: What's Behind It?
Boston Scientific rides on strong neuromodulation momentum as sales climb, new technologies gain traction and recent acquisitions expand its pain-treatment reach.
Boston Scientific Corporation (BSX) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Boston Scientific Corporation ( BSX ) 7th Annual Wolfe Research Healthcare Conference November 18, 2025 8:00 AM EST Company Participants Ken Stein - Senior VP & Global Chief Medical Officer Lauren Tengler - Director of Investor Relations Conference Call Participants Michael Polark - Wolfe Research, LLC Presentation Michael Polark Wolfe Research, LLC Good morning. Welcome, everybody.
Wall Street Analysts Believe Boston Scientific (BSX) Could Rally 25.34%: Here's is How to Trade
The consensus price target hints at a 25.3% upside potential for Boston Scientific (BSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Boston Scientific Up 7% in a Month: How Should You Play the Stock?
BSX's month-long rally, strong Q3 beats and expansion into chronic pain solutions sharpen investor focus.
